Aspirin reduces the main incidence of stroke, but misses the goal of disability-free survival.

Recently, there have been several recent developments in the field of international medical health that continue to attract the attention of the industry and the public. A study published at ESC Congress 2026's Hot Line meeting on the cover of the New England Journal of Medicine shows that researchers have not significantly improved disability-free survival rates by reducing torvastatin to 30% in older adults. Based on the findings of the ESC Congress 2026 Hot Line meeting, published at the 2026 ESC Congress 2026 Hot Line meeting.

It is commonly used to manage high cholesterol levels in people between the ages of 45 and 75 years. Due to its proven benefits in reducing the risk of heart attack and stroke, the uncertainty about the risks and benefits of it in preventing cardiovascular events in the elderly is due to the lack of adequate representation in major clinical trials of other it drugs. An estimated 21,000 older Australians are expected to experience major cardiovascular events, such as heart attacks and strokes, each year.

The Stray Trial was the first large double-blind trial to study whether statins can be used as the primary preventive measure to help them live longer, healthier lives in older people aged 70 and over. The trial, led by Sophia Zoungas, a scientist at the Department of General Clinical Medicine in Australia, recruited older people aged 70 and over as subjects. In total, 9,971 participants randomized (1, 1).

The average age of the study population was 74. 7 years. 52% were women.

The two main endpoints were major cardiovascular events, defined as cardiovascular death, nonfatal myocardial infarction, stroke or coronary angiogenesis, and disability-free survival, defined as free to survive without dementia and physical disability. The results showed that the aspirin group had a 30% lower risk of cardiovascular disease compared to the placebo group: HR 0. 70; 95% CI 0.

61 to 0. 82). However, the risk of death, dementia or persistent disability in the aspirin group was not significantly lower than in the placebo group (12.

8% vs. 5. 9%).

6. 0% vs. 8.

3%; hazard ratio [HR] 0. 70; 95% confidence interval [CI] 0. 61 to 0.

82; p<0. 001) (6. 0% vs.

8. 3%; hazard ratio [HR] 0. 70; 95% confidence interval [CI] 0.

61 to 0. 82; p<0. 001) However, the risk of death, dementia or persistent disability in the aspirin group was not significantly lower than in the placebo group: 12.

8% vs. 5. 9%) 95% confidence interval [CI] 0.

61 to 0. 82; p<0. 001)  As the ageing population of the world increases dramatically, answering fundamental questions has become essential.

Specifically, there has been a significant increase in muscle, liver and diabetes-related adverse events in both groups compared to the aspirin group. However, the incidence of all serious adverse events was low in both groups, reflecting to some extent the lower incidence of non-diabetic adverse events in the aspirin group, which may have a positive effect on the health benefits of the aspirin group. It should be noted that the above content is based on international public research, for reference in HealthCop, and does not constitute clinical advice.